Boosting research and development into polycystic kidney disease
Polycystic kidney disease (PKD) is the world’s most common inherited kidney disease with significant unmet needs and limited treatment options. Together with the PKD Charity, we’re committed to boosting research and development into PKD. We are forming a new PKD Research Consortium that will bring together scientific and clinical experts to accelerate treatment development and transform the lives of people living with PKD.
Our vision for the PKD Research Consortium
Our aim for the consortium is to combine experimental modelling, genetic and clinical data to generate insights and identify ways to treat the disease. The consortium will drive collaboration in this area and find new targets for drug development, or repurposing, to improve outcomes for patients.
Consultancy support needed
We’re looking for a consultancy who can undertake a scoping study to help us establish the PKD Research Consortium.
The proposed scoping study will be required to include:
- governance guidance and support
- information collection from stakeholders and intended academic centres
- identifying the barriers and opportunities for clinical trials.
Find out more
For more information about the PKD Research Consortium, and the scoping study requirements, download our PKD Consortium Consultancy Briefing document. Alternatively, if you have any questions or would like to discuss it further, contact Alan Greenberg, PKD Charity chair of trustees.
If your organisation can help support us, please send an expressions of interest to [email protected] by 31 July 2023.
Get our e-newsletter
Stay up to date with our kidney research news, events and ways to get involved.